A March 2017 mutual recognition agreement on pharmaceutical inspections between the US and the EU was already having an impact on inspections in Asia before it took full effect 11 July, data from both governments' inspectorates shows.
The agreement enabled both regions to rely more on each other’s inspections and free up resources to inspect other regions like Asia. The data show a significant shift is already underway, particularly with European inspections